U.S. FDA Approves Athena Bioscience’s New Drug Application (NDA) for QDOLO™ (tramadol hydrochloride) Oral Solution

Athena Bioscience, LLC, a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved QDOLO™ (tramadol hydrochloride) Oral Solution 5mg/1mL C-IV, an opioid agonist indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Full story.